Researchers analyzed data on 1,400 chronic obstructive pulmonary disease patients in the U.S. and found that those who took roflumilast daily had a lower 30-day hospital readmission rate from any cause and experienced fewer monthly COPD exacerbations than those who didn't use the drug. The study was presented at the annual meeting of the American College of Chest Physicians.

Related Summaries